| Literature DB >> 31459957 |
Daniel Carbajo1,2, Ayman El-Faham3,4, Miriam Royo1,2, Fernando Albericio1,2,3,5,6.
Abstract
The number of peptide-based active pharmaceutical ingredients (APIs) has increased enormously in recent years. Furthermore, the emerging new peptide drug candidates are more complex and larger. For the industrial solid-phase synthesis of C-carboxylic acid peptides, the two main resins available, Wang and chlorotrityl chloride (CTC), have a number of drawbacks. In this context, resins that form an amide bond with the first amino acid are more robust than Wang and CTC resins. Here, we address the use of the backbone (BAL) resin for the synthesis of the peptide liraglutide. The BAL resin, in conjunction with the use of pseudoprolines to avoid aggregation, allows the stepwise solid-phase synthesis of this API in excellent purity and yield.Entities:
Year: 2019 PMID: 31459957 PMCID: PMC6648002 DOI: 10.1021/acsomega.9b00974
Source DB: PubMed Journal: ACS Omega ISSN: 2470-1343
Figure 1Options for resin anchoring in solid-phase peptide synthesis: C-terminal anchoring (most used); side-chain anchoring (very useful for trifunctional first amino acids); N-terminal anchoring (not recommended); backbone anchoring (this work).
Figure 2General example of the BAL linker use.
Figure 3Sequence of liraglutide.
Figure 4Initial design of the synthetic scheme for liraglutide.
Figure 5HPLC trace of the crude peptide under different conditions. (A) HCTU/DIEA, no pseudoprolines; (B) pseudoprolines for Val17-Ser18; (C) pseudoprolines for Phe13-Thr14 and Val17-Ser18; and (D) pseudoprolines for Gly11-Thr12, Phe13-Thr14, and Val17-Ser18. (A, B) 10–100% H2O:ACN (0.1% TFA in 13 min), 220 nm; (C, D) 5–100% H2O:ACN (0.1% TFA in 13 min), 220 nm.
Purities Obtained Using the Different Methods for Liraglutide Sequence Completiona
| # | pseudoprolines | C. reagents | purity (%) |
|---|---|---|---|
| (not shown) | none | DIC/Oxyma | <5 |
| A | none | HCTU/DIEA | 14 |
| B | Val17-Ser18 | HCTU/DIEA | 55 |
| C | Phe13-Thr14 and Val17-Ser18 | HCTU/DIEA | 71 |
| D | Gly11-Thr12, Phe13-Thr14 and Val17-Ser18 | HCTU/DIEA | 91 |
HPLC traces are shown in Figure .
Figure 6HPLC trace of final liraglutide (A) before purification and (B) after purification (5–100% ACN (0.1% TFA) in 10 min, 220 nm).